50% rebalancing of relenza- secondary factor

I think there is another factor and thus higher royalities to Biota.


Firstly, if you use a figure of 300 million US population and a $US20 per course for relenza & 7% royality. You can run up these numbers



1. Old Pandemic Stockpile mix: 80% Tamiflu, 20% Relenza

Biota royality from this market alone is USD 13.4 million.


2. New Pandemic Stockplie mix: 50% Tamiflu, 50% Relenza


Biota royality from this market alone is USD 33.6 million

Secondary factor

If the stockpile plan follows WHO recommendation of 50% population coverage instead of 20% coverage

then the royalty number is USD 52.5 million

With the EU, Japan, Canada etc thrown in the mix, the numbers looks quite interesting